Alemtuzumab improves MRI outcomes regardless of subgroup versus interferon beta-1a in relapsingremitting MS patients who relapsed on prior therapy

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2014
This article has no abstract
Epistemonikos ID: dd5303efefe5e801feb17fca33871b24a1d39239
First added on: Apr 30, 2026